PBI100 / AstraZeneca, Biohaven - LARVOL DELTA

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Pyramid Biosciences | Recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Pyramid Biosciences

New P1 trial • Dermatology • Immunology • Psoriasis

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Pyramid Biosciences | Recruiting ➔ Completed

Trial completion

Pyramid Biosciences Announces Initial Closing of Series B Financing for Clinical Program Acceleration (Businesswire) - "Pyramid Biosciences, Inc....announced the initial close of its Series B financing. The financing will support the clinical development of multiple programs focused on novel tropomyosin receptor kinase (TRK) modulators....Pyramid Biosciences has raised more than $60 million USD to date."

Financing • Atopic Dermatitis • Dermatology

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: Pyramid Biosciences

Clinical • New P1 trial

Pyramid Biosciences Secures $28 Million in Funding to Accelerate Clinical Programs (Businesswire) - "Pyramid Biosciences...today announced the close of $28 million USD in funding. The financing will accelerate the growth of Pyramid Biosciences’ programs focused on novel tropomyosin receptor kinase (TRK) modulators in oncology and dermatology disorders....Pyramid Biosciences is developing PBI-100 for a range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis."

Financing • Atopic Dermatitis • Dermatology